Diagnosis of Hodgkin lymphoma in the modern era.
Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES.
Br J Haematol. 2019 Jan;184(1):45-59. doi: 10.1111/bjh.15614. Epub 2018 Nov 8.
Classic Hodgkin lymphoma.
Kahn J, Dabaja B, Wu S, Kelly K, Berkahn L, Pavlovsky A, Sureda A, LaCasce A.
Hematol Oncol. 2024 Nov;42(6):e3239. doi: 10.1002/hon.3239. Epub 2023 Dec 1.
Hodgkin's lymphoma.
Tsang RW, Hodgson DC, Crump M.
Curr Probl Cancer. 2006 May-Jun;30(3):107-58. doi: 10.1016/j.currproblcancer.2006.04.001.
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.
Eichenauer DA, Borchmann P.
Leuk Lymphoma. 2025 May;66(5):830-837. doi: 10.1080/10428194.2024.2447886. Epub 2025 Jan 2.
EBV-related primary splenic lymphocyte-depleted classical Hodgkin lymphoma.
Parekh V, Peker D.
J Clin Pathol. 2015 Nov;68(11):947-50. doi: 10.1136/jclinpath-2015-203145. Epub 2015 Jul 20.
Frequency of epstein-barr virus in classical hodgkin Lymphoma.
Azhar M, Din HU, Muhammad I, Hashmi SN, Akhtar F.
J Ayub Med Coll Abbottabad. 2016 Apr-Jun;28(2):271-275.
Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
Karube K, Niino D, Kimura Y, Ohshima K.
Pathol Res Pract. 2013 Apr;209(4):201-7. doi: 10.1016/j.prp.2012.11.003. Epub 2013 Mar 9.
[Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis].
Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K.
Rinsho Ketsueki. 2017;58(7):772-775. doi: 10.11406/rinketsu.58.772.
XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH, Hoppe RT.
Hematol Oncol. 2015 Jun;33 Suppl 1:90-5. doi: 10.1002/hon.2226.
Ovanligt symtom med hög klinisk valör vid Hodgkins lymfom.
Lanke E, Relander T.
Lakartidningen. 2024 Aug 20;121:24002.
